F
Fangxue Yan
Researcher at University of Pennsylvania
Publications - 6
Citations - 692
Fangxue Yan is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Tumor microenvironment & Immunotherapy. The author has an hindex of 6, co-authored 6 publications receiving 388 citations. Previous affiliations of Fangxue Yan include Peking University.
Papers
More filters
Journal ArticleDOI
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li,Katelyn T. Byrne,Fangxue Yan,Taiji Yamazoe,Zeyu Chen,Timour Baslan,Lee P. Richman,Jeffrey H. Lin,Yu H. Sun,Andrew J. Rech,David Balli,Ceire A. Hay,Yogev Sela,Allyson J. Merrell,Shannon M. Liudahl,Naomi Gordon,Robert J. Norgard,Salina Yuan,Sixiang Yu,Timothy Chao,Shuai Ye,T.S. Karin Eisinger-Mathason,Robert B. Faryabi,John W. Tobias,Scott W. Lowe,Scott W. Lowe,Lisa M. Coussens,E. John Wherry,Robert H. Vonderheide,Ben Z. Stanger +29 more
TL;DR: A library of congenic tumor cell clones from an autochthonous mouse model of pancreatic adenocarcinoma is established, identifying heterogeneous and multifactorial pathways regulating tumor‐cell‐intrinsic mechanisms that dictate the immune microenvironment and thereby responses to immunotherapy.
Journal ArticleDOI
Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2)
Nune Markosyan,Jinyang Li,Yu H. Sun,Lee P. Richman,Jeffrey H. Lin,Fangxue Yan,Liz Quinones,Yogev Sela,Taiji Yamazoe,Naomi Gordon,John W. Tobias,Katelyn T. Byrne,Andrew J. Rech,Garret A. FitzGerald,Ben Z. Stanger,Robert H. Vonderheide +15 more
TL;DR: The findings warrant clinical trials testing the effectiveness of therapies combining EPHA2-TGFβ-PTGS2 pathway inhibitors with anti-tumor immunotherapy, and may change the treatment of notoriously therapy-resistant pancreatic adenocarcinoma.
Journal ArticleDOI
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
Jinyang Li,Salina Yuan,Robert J. Norgard,Fangxue Yan,Yu H. Sun,Il Kyu Kim,Allyson J. Merrell,Yogev Sela,Yanqing Jiang,Natarajan V. Bhanu,Benjamin A. Garcia,Robert H. Vonderheide,Andres Blanco,Ben Z. Stanger +13 more
TL;DR: An in vivo CRISPR screen was performed and lysine demethylase 3A (KDM3A) was identified as a potent epigenetic regulator of immunotherapy response in PDA and the potential of EGFR inhibitors as immunotherapy sensitizers in Pda was highlighted.
Journal ArticleDOI
Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
Jinyang Li,Salina Yuan,Robert J. Norgard,Fangxue Yan,Taiji Yamazoe,Andres Blanco,Ben Z. Stanger +6 more
TL;DR: Examination of the role of the ubiquitin-specific protease 22 (USP22) as a regulator of the immune tumor microenvironment (TME) in PDA indicated that USP22 regulates immune infiltration and immunotherapy sensitivity in preclinical models of pancreatic cancer.
Journal ArticleDOI
Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia
TL;DR: This review will consider the role of two cellular processes, metabolism and epigenetics, in the development and progression of AML and highlight the studies that suggest an interconnection of therapeutic importance between the two.